Asbestos Mesothelioma Mesothelioma Treatment
Mesothelioma Alerts Conventional Treatments Experimental Treatments Mesothelioma Clinical Trials Mesothelioma Treatment by Stage Ask Your Doctor Cancer Centers Leading Mesothelioma Physicians Mesothelioma Articles & Abstracts Review Studies Case Studies Etiological Studies Diagnostic Studies Therapy Studies Mesothelioma Resources
News About ELSS Top Mesothelioma Doctors

Dr. David Sugarbaker
Boston, MA; Pioneered the "tri-modal" approach to treating malignant pleural mesothelioma...

Dr. Robert N. Taub
New York, NY; Prominent mesothelioma doctor and director of Columbia’s Mesothelioma Center...

Enter your information to receive a comprehensive mesothelioma packet free of charge at your doorstep within 24 hours.

First Name:

Last Name:

Address:

City:

ST:

Zip:

Home Phone:

Work Phone:

Cell Phone:

Email Address:

Have you or someone you know been diagnosed with mesothelioma?

Yes   No

Mesothelioma Treatment | Articles & Abstracts

Diagnostic Studies

Prognostic value of FDG PET imaging in malignant pleural mesothelioma

J Nucl Med 1999 Aug;40(8):1241-5
Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A
Department of Radiology, University of Pennsylvania Medical Center, Philadelphia, USA.

Despite several attempts at treating malignant pleural mesothelioma with various modalities, mortality remains high, with median survival between 12 and 18 mo. This disease may have a highly variable clinical course, with occasional long-term survivors. The purpose of this study was to assess whether tumor metabolic activity, as assessed by fluorodeoxyglucose (FDG) PET imaging, correlates inversely with survival.

METHODS: Twenty-eight patients with suspected mesothelioma underwent FDG PET scanning between September 1995 and May 1997. A diagnosis of mesothelioma was confirmed in 22. Fully corrected scans with attenuation correction of the entire chest were available in 17 patients with sufficient follow-up for survival analysis. Standardized uptake values (SUVs) were determined from the most active tumor site in each patient.

RESULTS: Seven patients died during follow-up, at a median period of 5.3 mo after FDG PET scanning. Follow-up information was available on the remaining 10 patients for a median period of 15.6 mo after the PET study. The mean SUV of the deceased patients was 6.6+/-2.9, compared with 3.2+/-1.6 among the combined survivors. The deceased patients had tumor SUVs that were highly correlated with duration of survival after the PET study (r = 0.87, P less than 0.05). The cumulative survival estimate by the Kaplan-Meier product limit method was 0.17 at 12 mo for the patients with tumor SUVs greater than the median value and 0.86 for those with lower SUVs. The survival distribution of the high SUV group showed significantly shorter survivals compared with the low SUV group (P less than 0.01).

CONCLUSION: Patients with highly active mesotheliomas on FDG PET imaging have a poor prognosis. High FDG uptake in these tumors indicates shorter patient survival.

PMID: 10450672
Click here to order or save article

If you have any questions regarding treatment options or your legal rights, please contact us.